Evidence map›Paper›PMID 37380715›Full record

ArticleAnnals of hematology2023

Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning.

Agathe Vely, Jérôme Paillassa, Christopher Nunes Gomes, Aurélien Giltat, Sophie Fouquet, Anne Lebreton, Marion Klemencie, Aline Clavert, Aline Tanguy-Schmidt, Mathilde Hunault-Berger and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Agathe VelyMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France.
Jérôme PaillassaMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France.
Christopher Nunes GomesMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France.
Aurélien GiltatMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France.
Sophie FouquetEtablissement Français du Sang, Angers, France.
Anne LebretonDépartement de Pharmacie, CHU d'Angers, Angers, France.
Marion KlemencieMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France.
Aline ClavertMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France.
Aline Tanguy-SchmidtMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France.
Mathilde Hunault-BergerMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France.
Corentin OrvainMaladies du Sang, CHU d'Angers, 4 Rue Larrey, 49933, Angers Cedex 9, France. corentin.orvain@chu-angers.fr.ORCID http://orcid.org/0000-0002-8717-0824
Centre Hospitalier Universitaire d'Angers · FRCentre National de la Recherche Scientifique · FRÉtablissement Français du Sang · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is part of the treatment strategy for some patients with high-risk lymphoma by improving survival with an acceptable toxicity profile. Although the BEAM (BCNU, etoposide, cytarabine, and melphalan) intensification regimen is the most used, the optimal dosing for each drug is unclear. Here, we retrospectively compared the outcome of 110 patients receiving higher (400 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationLymphomaAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineEtoposideHumansMelphalanRetrospective StudiesTransplantation, AutologousTransplantation ConditioningCarmustineCytarabineEtoposideMelphalanAutologous stem cell transplantationBEAMLymphomaToxicity

Identifiers

PMID37380715
OpenAlexW4382361983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.